Clinical Outcomes in Patients With Krukenberg Tumors From Colorectal Cancer.

Colorectal cancer Cytoreductive surgery Krukenberg tumors Metastatic colorectal cancer

Journal

The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340

Informations de publication

Date de publication:
24 May 2024
Historique:
received: 18 09 2023
revised: 08 04 2024
accepted: 22 04 2024
medline: 26 5 2024
pubmed: 26 5 2024
entrez: 25 5 2024
Statut: aheadofprint

Résumé

Ovarian metastases from gastrointestinal cancers such as colorectal cancer, also known as Krukenberg tumors (KTs), present unique challenges in management due to diagnostic uncertainty, decreased responsiveness to systemic therapies compared to other sites of metastasis, and associated debilitating symptomatology. Thus, we sought to characterize our institutional outcomes in metastatic colorectal cancer (mCRC) patients with KTs. A retrospective single-institution study was performed identifying adult, female patients from 2012 to 2021 with a diagnosis of mCRC. Patient demographics and clinicopathologic characteristics were collected and analyzed. Descriptive statistics, univariate and multivariable analyses, and Kaplan-Meier survival analyses were performed. Of 235 mCRC patients, 45 (19.1%) had KTs, 41 (91.1%) of whom had KTs in conjunction with other metastatic sites. Other initial sites of metastasis included the liver (n = 93, 39.6%), lung (n = 28, 11.9%), and peritoneum (n = 18, 7.7%). In the KT cohort, the median age was 48 y, 53.3% were non-Hispanic White, 100% had microsatellite stable tumors, 33.3% had Kristen Rat Sarcoma Virus (KRAS) mutations, and 6.7% had V-raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations. Fifty five point six percent of KT patients underwent cytoreductive surgery (CRS), 24.4% underwent palliative debulking, and 20% underwent no surgical intervention. Reasons for not undergoing CRS were disease-related (n = 14, 70%), due to poor performance status (n = 1, 5%), or both (n = 5, 25%). Five-year overall survival was 48.2% in KT patients who underwent CRS. Poor tumor grade was an independent predictor of mortality (hazard ratio 10.69, 95% confidence interval 1.20-95.47, P = 0.03). Almost 90% of our patient cohort with KTs from mCRC experience additional sites of metastasis. Around half of KT patients who underwent CRS were alive at 5 y.

Identifiants

pubmed: 38795557
pii: S0022-4804(24)00200-2
doi: 10.1016/j.jss.2024.04.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-352

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Auteurs

Arsha Ostowari (A)

Department of Surgery, University of California, Irvine Medical Center, Orange, California.

Bima J Hasjim (BJ)

Department of Surgery, University of California, Irvine Medical Center, Orange, California; Department of Transplant Surgery, Northwestern University, Chicago, Illinois.

Leena Lim (L)

University of California Irvine School of Medicine, Irvine, California.

Jingjing Yu (J)

Department of Surgery, University of California, Irvine Medical Center, Orange, California.

Lily Nguyen (L)

Department of Surgery, University of California, Irvine Medical Center, Orange, California.

Farshid Dayyani (F)

Division of Hematology/Oncology, Department of Medicine, University of California, Irvine Medical Center, Orange, California; Chao Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California.

Jason Zell (J)

Division of Hematology/Oncology, Department of Medicine, University of California, Irvine Medical Center, Orange, California; Chao Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California.

May Cho (M)

Division of Hematology/Oncology, Department of Medicine, University of California, Irvine Medical Center, Orange, California; Chao Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California.

Maheswari Senthil (M)

Chao Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California; Division of Surgical Oncology, Department of Surgery, University of California, Irvine Medical Center, Orange, California.

Oliver S Eng (OS)

Chao Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California; Division of Surgical Oncology, Department of Surgery, University of California, Irvine Medical Center, Orange, California. Electronic address: ostowari@hs.uci.edu.

Classifications MeSH